CYTOGAM: A Demonstrated Safety Profile2

CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) has a favorable safety profile, with an incidence of adverse events of <6.0% of all infusions.

The most frequent adverse reactions observed during clinical trials of CYTOGAM were flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing. The incidence of these reactions during the clinical trials was < 6.0% of all infusions, and such reactions were most often related to infusion rates. A decrease in blood pressure was observed in 1 of 1039 infusions in clinical trials of CYTOGAM.

IGIV (human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. The incidence of these reactions during the clinical trials was <6.0% of all infusions and such reactions were most often related to infusion rates.

Please see full Prescribing Information for full safety profile.

References: 1. Pharmacy and Therapeutics Committee. CYTOGAM® Cytomegalovirus Immune Globulin Intravenous (Human). P&T Product Profiler. 2010;35(3):1-23. 2. CYTOGAM [package insert]. Kamada Inc.; September 2022.   

You are now leaving the CYTOGAM site

Links to related resources are provided as a service to viewers. Kamada Inc. is not responsible for the content of linked sites.